Is btai bullish

The sentiment among institutional investors regarding BioXcel Therapeutics, Inc. (BTAI) is currently neutral to slightly bearish. Here's the analysis to support this conclusion: 1. **Institutional Ownership and Sentiment**: - As of July 11, 2024, BTAI has 166 institutional owners and shareholders holding a total of 10,038,824 shares, which represents a significant portion of the company. However, this does not necessarily indicate sentiment, as institutions can hold shares passively as part of their diversified portfolios. - The Fund Sentiment Score is not available, but the absence of a significant number of institutions filing 13D/G reports within the last year suggests a lack of strong positive sentiment. 2. **Recent Performance and Insider Ownership**: - The share price has experienced a significant decline from $11.38 on July 12, 2023, to $1.20 on July 11, 2024, which could be a factor in the neutral to slightly bearish sentiment. - Insider ownership is low, with insiders owning under 1% of the company, which may not provide a strong signal regarding institutional sentiment. 3. **Public and Institutional Profit**: - Despite the decline in share price, institutions have profited from the market cap increase of $43 million, indicating some level of positive sentiment. - Retail investors have reaped the most benefits after a 66% price gain, which could suggest that institutional investors are less bullish compared to retail investors. 4. **Blogger Sentiment**: - The overall sentiment among bloggers is neutral, with no clear trend of bullish or bearish predictions. - The lack of recent top blogger opinions may indicate a lack of strong sentiment driving the stock. In conclusion, while institutional ownership is high, the absence of strong positive sentiment indicators and the recent significant price decline suggest a neutral to slightly bearish sentiment among institutional investors regarding BTAI.